研究者業績

北山 丈二

キタヤマ ジョウジ  (JOJI KITAYAMA)

基本情報

所属
自治医科大学 消化器外科 教授
学位
医学博士(東京大学)

J-GLOBAL ID
201801007452437948
researchmap会員ID
B000314953

Professor of Jichi Medical University
Department of Surgical Oncology
Research field is Tumor Biology and main clinical work is the treatment of peritoneal metastasis of gastric cancer (intraperitoneal chemotherapy).

研究キーワード

 2

論文

 601
  • J. Kitayama, T. Juji, Y. Atomi, A. Kuroda, T. Muto, M. Kobayashi, Y. Mitsui, M. Minami
    Journal of Immunology 151(3) 1663-1672 1993年  
    With an in vitro static system using HUVEC (human umbilical vein-derived endothelial cells) cultured on type I collagen gel, we investigated the transendothelial migration activities of II-2 activated killer (LAK) cells. Our results indicate that in comparison with unstimulated T cells, LAK cells exhibit strong transendothelial migration activity, as well as increased adhesiveness to HUVEC. Pretreatment of HUVEC for 24 h with rINF-γ, rTNF-α and rIL-1β enhanced the LAK cell migration. The increase in the percentage of migration of LAK cells was greater than that of the percentage of adhesion but significantly less than the increase in the percentage of migration of resting T cells. The results of blocking studies using mAb strongly suggest that the enhanced migration of LAK cell was probably attributed to nonspecifically increased binding to HUVEC and markedly enhanced chemokinetic activity that was dependent primarily on the LFA-1 molecule. Among LAK cells, there were considerable differences in the migration activities of the various phenotypes. CD8+T-LAK migrated preferentially to CD4+T-LAK. CD16+NK-LAK showed increased adhesion but somewhat decreased migration activities. However, rINF-γ treatment of HUVEC for 24 h promoted vigorous migration of CD16+ NK-LAK, which suggests that endothelium regulate the migration of LAK cells. Based on these observations, we proposed that LAK cells, if transferred into tumor feeding vessels, can migrate into tumor tissue in considerable numbers and efficiently make contact with individual tumor cells to produce preferable clinical effects.

MISC

 331

講演・口頭発表等

 1163

共同研究・競争的資金等の研究課題

 51